401 related articles for article (PubMed ID: 25185962)
1. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
[TBL] [Abstract][Full Text] [Related]
2. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
[TBL] [Abstract][Full Text] [Related]
4. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
[TBL] [Abstract][Full Text] [Related]
5. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
6. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
7. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
8. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
[TBL] [Abstract][Full Text] [Related]
9. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].
Rivera R; García-Doval I; Carretero G; Daudén E; Sánchez-Carazo J; Ferrándiz C; Herrera E; Alsina M; Ferrán M; López-Estebaranz JL; Gómez F; Herranz JM; Carrascosa JM; Vanaclocha F;
Actas Dermosifiliogr; 2011 Mar; 102(2):132-41. PubMed ID: 21377137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
11. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
12. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
[TBL] [Abstract][Full Text] [Related]
14. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
Dávila-Seijo P; Dauden E; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas M; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1942-1950. PubMed ID: 27329511
[TBL] [Abstract][Full Text] [Related]
15. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM; Vilavella M; Garcia-Doval I; Carretero G; Vanaclocha F; Daudén E; Gómez-García FJ; Herrera-Ceballos E; De la Cueva Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Peral F; Torrado R; Rivera R; Jiménez-Puya R; Mendiola MV; Ferrándiz C;
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):907-14. PubMed ID: 23848131
[TBL] [Abstract][Full Text] [Related]
16. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Dávila-Seijo P; Dauden E; Descalzo MA; Carretero G; Carrascosa JM; Vanaclocha F; Gómez-García FJ; De la Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; López-Estebaranz JL; Alsina M; Sánchez-Carazo JL; Ferrán M; Torrado R; Ferrandiz C; Rivera R; Llamas M; Jiménez-Puya R; García-Doval I;
J Invest Dermatol; 2017 Feb; 137(2):313-321. PubMed ID: 27677836
[TBL] [Abstract][Full Text] [Related]
17. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
García-Doval I; Hernández MV; Vanaclocha F; Sellas A; de la Cueva P; Montero D;
Br J Dermatol; 2017 Mar; 176(3):643-649. PubMed ID: 27258623
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis in elderly and non-elderly population: clinical and molecular features.
Napolitano M; Balato N; Ayala F; Patruno C; Patrì A; Megna M; Balato A
G Ital Dermatol Venereol; 2016 Dec; 151(6):587-595. PubMed ID: 26199090
[TBL] [Abstract][Full Text] [Related]
19. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
20. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
